Related Experiment Video
Updated: Jul 9, 2026
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease
Keiichiro Sakuma1, Hajime Nakamura, Takayuki Nakamura
1Department of Respiratory Medicine, Kyoto University Graduate School of Medicine, Kyoto. ksakuma@aichi-cc.jp
Objective:
Interstitial lung disease (ILD) is a severe adverse event of gefitinib therapy. However, the mechanism still remains unclear. The objective of this study was to examine whether or not oxidative stress, one of the common factors in drug-associated ILD, is involved in the pathogenesis of gefitinib-induced ILD.
Patients And Methods:
Using an enzyme-linked immunosorbent assay (ELISA), we measured the concentration of serum thioredoxin (Trx), a redox-active protein with antioxidative effects, in 44 patients treated with gefitinib, including three patients who had ILD.
Results:
In patients who had gefitinib-induced ILD, serum Trx levels were significantly elevated. They decreased after cessation of gefitinib therapy accompanying clinical improvement of ILD.
Conclusion:
It was suggested that oxidative stress may be involved as a part of mechanisms causing or worsening gefitinib-induced ILD.
